AZD1722 for phosphate lowering in dialysis patients

• Research type

  Research Study

• Full title

  A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre, Dose finding Study to evaluate the Efficiency, Safety and Tolerability of AZDI1722 to Treat Hyperphosphataemia in End-Stage Renal Disease on Haemodialysis(ESRD-HD)

• IRAS ID

  147318

• Contact name

  Graham Warwick

• Contact email

  graham.warwick@uhl-tr.nhs.uk

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2013-004319-33

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  14/SC/0104

• Date of REC Opinion

  10 Mar 2014

• REC opinion

  Favourable Opinion